[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO954073L - Sammensetninger for inhibisjon, kontroll og regresjon av angiogenesen inneholdende hyaluronsyre og NSAID - Google Patents

Sammensetninger for inhibisjon, kontroll og regresjon av angiogenesen inneholdende hyaluronsyre og NSAID

Info

Publication number
NO954073L
NO954073L NO954073A NO954073A NO954073L NO 954073 L NO954073 L NO 954073L NO 954073 A NO954073 A NO 954073A NO 954073 A NO954073 A NO 954073A NO 954073 L NO954073 L NO 954073L
Authority
NO
Norway
Prior art keywords
hyaluronic acid
control
nsaids
regression
inhibition
Prior art date
Application number
NO954073A
Other languages
English (en)
Other versions
NO954073D0 (no
Inventor
Derek A Willoughby
Chandan Alam
Samuel Simon Asculai
Rudolf Edgar Falk
David William Harper
Original Assignee
Hyal Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hyal Pharma Corp filed Critical Hyal Pharma Corp
Publication of NO954073D0 publication Critical patent/NO954073D0/no
Publication of NO954073L publication Critical patent/NO954073L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Filters For Electric Vacuum Cleaners (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

Anvendelse av (a) et Ikke-steroldalt antl-inflamma- torisk middel, og (b) hyaluronsyre og/eller salter derav og/eller homologer, analoger, derivater, komplekser, estere, fragmenter og subenheter av hyaluronsyre, for fremstilling av en farmasøytisk sammensetning for inhlberlng, kontrollerlng og/eller regresjon av angiogenesen l en terapi hvor doserlngs- mengdene fra sammensetningen hver omfatter: (a) en terapeutisk effektiv mengde av komponent (a); og (2) en terapeutisk effektiv mengde av hyaluronsyre og/eller salter derav og/eller en terapeutisk effektiv mengde hyaluronsyre og/eller salter derav og/eller homologer, analoger, derivater, komplekser, estere, fragmenter og subenheter av hyaluronsyre, l det den farmasøytiske sammensetningen er kjennetegnet ved at det for hver doserlngsmengde av den farmasøytiske sammensetningen vil mengden av komponentene (a) og (b) inhibere, kontrollere og/eller forhindre angiogenese.
NO954073A 1993-04-16 1995-10-13 Sammensetninger for inhibisjon, kontroll og regresjon av angiogenesen inneholdende hyaluronsyre og NSAID NO954073L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA002094203A CA2094203A1 (en) 1993-04-16 1993-04-16 Inhibition of angiogenesis
PCT/CA1994/000207 WO1994023725A1 (en) 1993-04-16 1994-04-15 Compositions, for inhibition, control and regression of angiogenesis, containing hyaluronic acid and nsaid
CN94192096A CN1123005A (zh) 1993-04-16 1994-04-15 用于抑制、控制和消退血管生成的含有透明质酸和nsaid的组合物

Publications (2)

Publication Number Publication Date
NO954073D0 NO954073D0 (no) 1995-10-13
NO954073L true NO954073L (no) 1995-12-04

Family

ID=37089291

Family Applications (1)

Application Number Title Priority Date Filing Date
NO954073A NO954073L (no) 1993-04-16 1995-10-13 Sammensetninger for inhibisjon, kontroll og regresjon av angiogenesen inneholdende hyaluronsyre og NSAID

Country Status (18)

Country Link
EP (1) EP0695187B1 (no)
JP (1) JPH08508505A (no)
CN (1) CN1123005A (no)
AT (1) ATE226827T1 (no)
AU (2) AU694113B2 (no)
BR (1) BR9405781A (no)
CA (1) CA2094203A1 (no)
CZ (1) CZ267995A3 (no)
DE (1) DE69431623D1 (no)
FI (1) FI954914A (no)
HU (2) HUT74462A (no)
IL (1) IL109293A (no)
NO (1) NO954073L (no)
PL (1) PL306806A1 (no)
SG (1) SG48924A1 (no)
SK (1) SK126595A3 (no)
WO (1) WO1994023725A1 (no)
ZA (1) ZA942597B (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5935860A (en) * 1995-03-07 1999-08-10 The George Washington University Use of uteroglobin expression as a molecular marker for prostatic intraepithelial neoplasia
CA2154103C (en) * 1995-07-18 1998-02-24 Samuel Simon Asculai Treatment of mucous membrane disease, trauma or condition and for the relief of pain
US6875753B1 (en) 1996-03-14 2005-04-05 The Governors Of The University Of Alberta Methods for cell mobilization using in vivo treatment with hyaluronan (HA)
EP2298300A1 (en) * 1996-11-05 2011-03-23 The Children's Medical Center Corporation Compositions for inhibition of anglogenesis comprising thalidomide and aspirin
WO1998042329A1 (fr) * 1997-03-21 1998-10-01 Mitsubishi Chemical Corporation Preventifs et/ou remedes destines a des affections provoquees par une neovascularisation anormale
US6596703B1 (en) 1997-07-11 2003-07-22 Jagotec Ag Promotion of wound healing utilizing steroids having reduced deteriorous systemic side effects typical of glucocorticoids, mineralocorticoids and sex steroids
ATE376824T1 (de) 1999-01-13 2007-11-15 Alchemia Oncology Pty Ltd Verwendung von hyaluronan zur herstellung eines medikaments zur erhöhung der wirksamkeit von zytotoxischen arzneimitteln
JP4587148B2 (ja) * 2000-03-24 2010-11-24 生化学工業株式会社 平滑筋細胞増殖促進剤
US9066919B2 (en) 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
AUPQ879500A0 (en) 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
ITPD20020003A1 (it) * 2002-01-11 2003-07-11 Fidia Advanced Biopolymers Srl Biomateriali a base di acido ialuronico come terapia anti-angiogenicanella cura dei tumori.
ITMI20040347A1 (it) * 2004-02-26 2004-05-26 Pharma Medical Ltd Nuovo farmaco di associazione
CN101287474B (zh) 2005-07-27 2014-08-20 阿尔卡米亚肿瘤学股份有限公司 使用乙酰透明质酸的治疗方案
CN101287475B (zh) 2005-09-07 2012-11-14 阿尔卡米亚肿瘤学股份有限公司 包含透明质酸和治疗抗体的治疗组合物以及制药用途
EA015702B1 (ru) * 2007-05-28 2011-10-31 Винченцо Массимо Ломбардо Противовоспалительная и анальгетическая композиция для местного применения в области опорно-двигательного аппарата животного
EP2567697A1 (en) * 2011-09-12 2013-03-13 Almirall, S.A. Topical pharmaceutical compositions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4141973A (en) * 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
US5095037B1 (en) * 1989-12-21 1995-12-19 Nissho Kk Combined anti-inflammatory agent
CA2061566C (en) * 1992-02-20 2002-07-09 Rudolf E. Falk Treatment of disease employing hyaluronic acid and nsaids

Also Published As

Publication number Publication date
IL109293A (en) 1999-01-26
AU6561694A (en) 1994-11-08
SG48924A1 (en) 1998-05-18
DE69431623D1 (de) 2002-12-05
EP0695187B1 (en) 2002-10-30
IL109293A0 (en) 1994-07-31
BR9405781A (pt) 1996-01-16
AU6994198A (en) 1998-07-23
PL306806A1 (en) 1995-04-18
EP0695187A1 (en) 1996-02-07
CN1123005A (zh) 1996-05-22
HU211954A9 (en) 1996-01-29
ATE226827T1 (de) 2002-11-15
SK126595A3 (en) 1997-03-05
AU694113B2 (en) 1998-07-16
JPH08508505A (ja) 1996-09-10
FI954914A (fi) 1995-11-06
HU9500113D0 (en) 1995-03-28
FI954914A0 (fi) 1995-10-16
CZ267995A3 (en) 1996-10-16
CA2094203A1 (en) 1994-10-17
NO954073D0 (no) 1995-10-13
HUT74462A (en) 1996-12-30
ZA942597B (en) 1995-02-08
WO1994023725A1 (en) 1994-10-27

Similar Documents

Publication Publication Date Title
NO954073L (no) Sammensetninger for inhibisjon, kontroll og regresjon av angiogenesen inneholdende hyaluronsyre og NSAID
NZ235877A (en) Composition comprising acetaminophen or nsaid and an h 1 or h 2 receptor blocker and/or proton pump inhibitor for treating overindulgence
AU3664401A (en) Platelet adp receptor inhibitors
BR9806060A (pt) Composto, composição farmacêutica e processos para tratar um paciente sofrendo de um estado doentio, para inibir o fator xa, e, para inibir a formação de trombina.
HK1157331A1 (zh) 血小板 受體抑制劑
BR9814327A (pt) Compostos de tiouréia e benzamida, composições e pro-cessos para tratamento ou prevenção de doenças infla-matórias e arteriosclerose
BR9814389A (pt) Forma de dosagem farmacêutica revestida entérica, processo para a preparação da mesma, uso desta, pelota ou tablete encamado para a mesma, e, processos para melhorar a inibição da secreção de ácido gástrico, e para melhorar o efeito terapêutico no tratamento de distúrbios gastrointestinais associados com secreção de ácido em excesso
DK645189A (da) Sulfonsyresubstituerede, aromatiske steroider, farmaceutiske midler indeholdende disse samt deres anvendelse
DE69825603D1 (de) 2,3,5-trisubstituierte pyridine als inhibitoren von cyclooxygenase-2
DK0773022T3 (da) Farmaceutisk sammensætning til behandling af rhinitis indeholdende sympathomimetika og pantothenol og/eller pantothensyre
PT97395A (pt) Processo para a preparacao de 2,9-di-substituidas-4h-pirido{1,2-a}-pirimidin-4-onas e de composicoes farmaceuticas que os contem
BR9813319A (pt) Composto, composição farmacêutica para tratamento de infecções bacterianas, e, processos para tratar infecções bacterianas e para preparar um composto
AR020226A1 (es) Compuestos para la inhibicion de la secrecion de acido gastrico, procesos para su preparacion, formulaciones farmaceuticas y uso de dichos compuestos parapreparar medicamentos
FI102964B1 (fi) Terapeuttisia yhdisteitä
DE69029693D1 (de) Hydantoin- oder Imidazolidintrionderivate zur Vorbeugung oder Behandlung von Niereninsuffizienz
FI923664A (fi) Piperidinderivat
WO1997035573A3 (en) Nsaids in the treatment of pruritus
PL371264A1 (en) Method for the treatment of bone disorders
CA2301590A1 (en) 2-aminopyridines as inhibitors of cyclooxygenase-2
IL149830A0 (en) Dimethylamino (ethylidene) thioamide derivatives, process for their preparation and use thereof in the preparation of angiogenesis inhibitors
CA2315826A1 (en) Carboxyl acid substituted heterocycles as metalloproteinase inhibitors